196 related articles for article (PubMed ID: 29029412)
1. The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.
Kim JY; Jeong HS; Chung T; Kim M; Lee JH; Jung WH; Koo JS
Oncotarget; 2017 Sep; 8(39):65064-65076. PubMed ID: 29029412
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
3. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
5. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
6. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
9. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
[TBL] [Abstract][Full Text] [Related]
10. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
11. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
13. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract][Full Text] [Related]
14. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
[TBL] [Abstract][Full Text] [Related]
15. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
Gunia S; Kakies C; Erbersdobler A; Koch S; May M
J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
[TBL] [Abstract][Full Text] [Related]
16. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
17. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
18. Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3.
Ohashi R; Namimatsu S; Sakatani T; Naito Z; Takei H; Shimizu A
J Surg Oncol; 2018 Sep; 118(3):557-567. PubMed ID: 30098295
[TBL] [Abstract][Full Text] [Related]
19. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
[TBL] [Abstract][Full Text] [Related]
20. Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lee LH; Swanson PE; Tang PA; Bigras G; Yang H
Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):25-31. PubMed ID: 26371428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]